CD274 and neoplasm: Tumors exploit multiple escape mechanisms to evade immune recognition, such as PD-L1 negative or low expression, low tumor mutational burden (TMB) and low neoantigen levels, tumor antigen presentation dysfunction, etc. [16,17,18].